Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors
Publisher DOI
PubMed ID
20828803
Abstract
Receptors for luteinizing hormone-releasing hormone (LHRH) can be utilized for targeted chemotherapy of cytotoxic LHRH analogs. The compound AEZS-108 (previously AN-152) consists of [D-Lys?]LHRH linked to doxorubicin. The objectives of this first study in humans with AESZ-108 were to determine the maximum tolerated dose and to characterize the dose-limiting toxicity, pharmacokinetics, preliminary efficacy, and hormonal effects.
Date Issued
2010
Publication Type
Article
Language(s)
en
Author(s)
Emons, Günter | |
Kaufmann, Manfred | |
Gorchev, Grigor | |
Tsekova, Valentina | |
Gründker, Carsten | |
Hanker, Lars C | |
Velikova, Maya | |
Sindermann, Herbert | |
Engel, Jürgen | |
Schally, Andrew V |
Additional Credits
Journal
Gynecologic oncology
Publisher
Elsevier
ISSN
0090-8258
Access(Rights)
metadata.only